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aA and aB crystallins, members of the small heat
shock protein family, prevent aggregation of proteins by
their chaperone-like activity. These two proteins, al-
though very homologous, particularly in the C-terminal
region, which contains the highly conserved “a-crystal-
lin domain,” show differences in their protective ability
toward aggregation-prone target proteins. In order to
investigate the differences between aA and aB crystal-
lins, we engineered two chimeric proteins, aANBC and
aBNAC, by swapping the N-terminal domains of aA and
aB crystallins. The chimeras were cloned and expressed
in Escherichia coli. The purified recombinant wild-type
and chimeric proteins were characterized by fluores-
cence and circular dichroism spectroscopy and gel per-
meation chromatography to study the changes in sec-
ondary, tertiary, and quaternary structure. Circular
dichroism studies show structural changes in the chi-
meric proteins. aBNAC binds more 8-anilinonaphtha-
lene-1-sulfonic acid than the aANBC and the wild-type
proteins, indicating increased accessible hydrophobic
regions. The oligomeric state of aANBC is comparable to
wild-type aB homoaggregate. However, there is a large
increase in the oligomer size of the aBNAC chimera.
Interestingly, swapping domains results in complete
loss of chaperone-like activity of aANBC, whereas
aBNAC shows severalfold increase in its protective abil-
ity. Our findings show the importance of the N- and
C-terminal domains of aA and aB crystallins in subunit
oligomerization and chaperone-like activity. Domain
swapping results in an engineered protein with signifi-
cantly enhanced chaperone-like activity.
a-Crystallin, a major lens protein having homology with
small heat shock proteins (1–3), prevents aggregation of other
proteins like a molecular chaperone (4). We had earlier shown
that a-crystallin can prevent photo-aggregation of g-crystallin,
which may have relevance in cataractogenesis (5). By using
various non-thermal modes of aggregation, it was shown that
chaperone-like activity of a-crystallin is temperature-depend-
ent. A structural perturbation above 30 °C enhances this activ-
ity severalfold (6, 7). In order to probe the molecular mecha-
nism of the chaperone-like activity and its enhancement upon
structural perturbation, we have been studying a-crystallin
and its constituent subunits. Our recent study on the aA and
aB homoaggregates showed that, despite high sequence homol-
ogy, these proteins differ in their stability, chaperone-like ac-
tivity, and the temperature dependence of this activity (8). This
study also indicated different roles for the two proteins in the
a-crystallin heteroaggregate in the eye lens and as separate
proteins in non-lenticular tissues. Several investigators have
introduced mutations in aA and aB crystallins to gain an
insight into the structure-function relation (9–12). Derham
and Harding in their recent review (13) list about 30 site-
directed mutations from different laboratories. These muta-
tions either result in some decrease or no change in the pro-
tective ability. It is interesting to note that point mutations in
both aA and aB crystallin, R116C and R120G, respectively,
result in significant loss of activity and are associated with
human diseases (14–19).
Human aA and aB crystallins are coded by three exons (20,
21) and are thought to have arisen due to gene duplication.
They share high sequence homology with the small heat shock
proteins, which are found in all organisms, from prokaryotes to
humans (22). aA and aB crystallins are constitutively ex-
pressed during normal growth and development. aA crystallin
is expressed predominantly in the eye lens with small amounts
being present in spleen and thymus (23), whereas aB crystallin
is expressed not only in the eye lens, but also in several other
tissues such as heart, skeletal muscle, placenta, lung, and
kidney (24, 25). The main function of these proteins in the lens
appears to provide transparency and prevent precipitation by
binding to other aggregation-prone proteins. In the lens, aA
and aB crystallins exist as heteroaggregates of approximately
800 kDa. Both the recombinant aA and aB crystallins exist as
high molecular mass oligomeric proteins of approximately 640
and 620 kDa, respectively (26). The size of these proteins can
vary a little depending on the pH and ionic strength, and they
differ in their structure, function, tissue expression, and abnor-
mal deposition in disease.
aB crystallin has a heat shock element upstream to the gene
and is induced during stress (3, 28). Apart from maintaining lens
transparency, its in vivo functions include interaction with inter-
mediate filaments (29) and regulation of cytomorphological rear-
rangements during development (30). aB crystallin is hyperex-
pressed in neurological disorders such as Alzheimer’s’ disease,
Creutzfeldt-Jacob disease, and Parkinson’s disease (31–33).
The charged C-terminal domain is conserved in all the mem-
bers of the small heat shock protein family, whereas the hy-
drophobic N-terminal domain is variable in length and se-
quence similarity (34). The N- and C-terminal domains are
thought to form two structural domains with an exposed C-
terminal extension (35). To investigate the role of the N-termi-
nal domains in the differential structural and functional prop-
erties of human aA and aB crystallins, we have swapped their
N-terminal domains coded by exon 1. A unique XmnI restric-
tion site at the beginning of the a-crystallin domain in a 20-
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nucleotide stretch in exon 2, with 100% sequence identity in
human aA and aB crystallin genes, has been used to create
chimeric proteins aANBC and aBNAC. We have used biophys-
ical methods to study the structural and functional properties
of wild-type aA and aB crystallins as well as the chimeras in
order to get an insight into the effect of swapping and the role
of the N-terminal domain in oligomerization and chaperone-
like activity.
EXPERIMENTAL PROCEDURES
Construction of Human Chimeric aA and aB Crystallins
aANBC Chimera—The 235-base pair NdeI-XmnI fragment of
pCR2.1-aA plasmid (16) was ligated to the 384-base pair XmnI-HindIII
fragment of pCR2.1-aB plasmid (16) to generate chimeric coding region
of aANBC. The aANBC chimera with NdeI-HindIII overhangs was then
ligated to NdeI-HindIII-linearized expression vector pET21a (Novagen)
to produce pET21a-aANBC.
aBNAC Chimera—The 247-base pair NdeI-XmnI fragment of
pCR2.1-aB was ligated to the 446-base pair XmnI-HindIII fragment of
pCR2.1-aA to generate the chimeric coding region of aBNAC. The
aBNAC chimera with NdeI-HindIII overhangs was ligated to NdeI-
HindIII-linearized pET21a to produce pET21a-aBNAC.
Sequencing of Human Chimeric aANBC and aBNAC Crystallins
Sequencing was done with T7 promoter primer using the dye termina-
tor cycle sequencing kit (Perkin-Elmer) in an 3700 ABI automated DNA
sequencer. The coding regions of both the aANBC and aBNAC chimeras
were found to be mutationless with no change in the reading frame.
Overexpression and Purification of Human Wild-type and
Chimeric aA and aB Crystallins
The expression plasmids (pET21a-aAwt, pET21a-aBwt, pET21a-
aANBC, and pET21a-aBNAC) were transformed into competent Esch-
erichia coli BL21(DE3) cells. Growth, induction, lysis of cells, and
purification of chimeric proteins was done as described for recombinant
wild-type aA and aB crystallins (26).
FPLC1 Gel Permeation Chromatography
Multimeric sizes of the wild-type and chimeric proteins were evalu-
ated on Superose-6 HR 10/30 prepacked column (dimensions: 10 3 300
mm, bed volume: 24 ml) with reference to high molecular mass stand-
ards (Sigma). Standards used were thyroglobulin (669 kDa), ferritin
(440 kDa), and catalase (232 kDa).
Fluorescence Measurements
Intrinsic Fluorescence—Intrinsic fluorescence spectra of wild-type
and chimeric proteins were recorded using a Hitachi F-4000 fluores-
cence spectrophotometer with the excitation wavelength of 295 nm. The
excitation and emission band passes were set at 5 and 3 nm, respec-
tively. Intrinsic fluorescence spectra were recorded using 0.2 mg/ml
protein in 10 mM phosphate buffer, which was incubated at 37 °C for 10
min.
8-Anilino-1-naphthalenesulfonic Acid (ANS) Binding—Wild-type
and chimeric proteins (0.2 mg/ml) in 10 mM phosphate buffer, pH 7.4,
containing 100 mM NaCl were equilibrated at 37 °C in the sample
holder of Hitachi F-4000 fluorescence spectrophotometer using a Julabo
thermostated water bath for 10 min. To these protein samples, 20 ml of
10 mM ANS was added. Fluorescence spectra were recorded with an
excitation wavelength of 365 nm. The excitation and emission band
passes were 5 and 3 nm, respectively.
Circular Dichroism Studies
Circular dichroism spectra were recorded using a Jasco J-715 spec-
tropolarimeter. All spectra reported are the average of 5 accumulations.
Far- and near-UV CD spectra were recorded using 0.05- and 1-cm
pathlength cuvettes, respectively.
Assay for Protein Aggregation
Chaperone-like activity of the wild-type and chimeric proteins was
studied by the insulin aggregation assay (6, 36). The extent of protec-
tion by the wild-type aA and aB crystallins and the chimeric proteins
was studied by incubating insulin (0.2 mg/ml) with various concentra-
tions of the wild-type and chimeric proteins for 10 min at 37 °C. Aggre-
gation was initiated by the addition of 20 ml of 1 M dithiothreitol (DTT)
after the incubation.
RESULTS AND DISCUSSION
Construction and Expression of the Chimeric Human aA and
aB Crystallins—Human aA and aB crystallin genes have a
unique site for the restriction enzyme XmnI at the beginning of
exon 2. A 20 nucleotide stretch at the XmnI site in both aA and
aB crystallins has 100% sequence identity. Swapping of the
domains does not disturb the reading frame (Fig. 1). Since
XmnI site is slightly into the exon II, the excised N-terminal
fragment has additional 15 amino acids. Of the 15 amino acids,
8 are identical and the rest are chemically conserved. Ligation
of the N-terminal domain of aA crystallin with the C-terminal
region of aB crystallin results in the chimeric polypeptide
aANBC crystallin, which is 171 amino acids long. Similarly,
the ligation of the N-terminal region of aB crystallin with
C-terminal domain of aA crystallin creates polypeptide aBNAC
crystallin that is 177 amino acids long. Henceforth, the chime-
ras are referred to as aANBC and aBNAC. Overexpression and
purification of the chimeric proteins was carried out as de-
scribed earlier for the wild-type proteins. The wild-type and
chimeric proteins were purified to greater than 95% homoge-
1 The abbreviations used are: FPLC, fast protein liquid chromatog-
raphy; ANS, 8-anilino-1-naphthalenesulfonic acid; DTT, dithiothreitol.
FIG. 1. Schematic description of the
design of chimeric constructs.
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neity, as judged by SDS-polyacrylamide gel electrophoresis
(data not shown), and moved as ;20-kDa proteins as expected.
Interestingly, when aANBC is eluted from a Mono Q ion ex-
change column with a 0–2 M NaCl gradient, it elutes at ;100
mM NaCl like the wild-type aB crystallin. On the other hand,
aBNAC elutes at ;350 mM NaCl, similar to wild-type aA
crystallin. The number of positively and negatively charged
amino acids are identical in wild-type aA crystallin and
aBNAC (Arg1Lys 5 20; Asp1Glu 5 25) and in wild-type aB
crystallin and aANBC (Arg1Lys 5 24; Asp1Glu 5 25). A
recently proposed model for a-crystallin suggests that the hy-
drophobic N-terminal domain is mostly buried in the oligomer
(37). Thus, the C-terminal domain may largely determine the
surface charge distribution of the proteins. This could be one of
the reasons for the similarity in Mono Q elution profiles of
wild-type proteins and chimeras that contain C-terminal re-
gions identical to those of the wild-type proteins.
Superose-6 Gel Permeation Chromatography—To investigate
the consequences of domain swapping on the molecular masses,
chimeric and wild-type proteins were chromatographed on a
FPLC Superose-6 gel filtration column (Fig. 2). The average
molecular masses of wild-type aA and aB crystallins were
observed to be ;640 and ;620 kDa, respectively. These sizes
are consistent with earlier reports (16, 26). The chimera
aANBC elutes at the same elution volume as that of wild-type
aB with an apparent molecular mass of ;620 kDa. However
the aBNAC chimera oligomerizes into large polydisperse ag-
gregates, with species exceeding 2000 kDa. This finding shows
an important difference in aA and aB crystallins. The aANBC
chimera consisting of the N-terminal domain of aA crystallin
and the C-terminal domain of aB crystallin still possesses the
oligomer size of wild-type aA and aB crystallins. Thus, it ap-
pears that the N-terminal domain of aB crystallin can be re-
placed by the N-terminal domain of aA crystallin with no
alteration in the oligomeric status. However, the N-terminal
domain of aB crystallin in fusion with the C-terminal domain of
aA crystallin forms very large aggregates, probably due to
altered packing of the subunits with an increase in intersub-
unit interaction. This kind of increase in the oligomer size was
earlier observed in the R116C mutant of aA crystallin (15). The
monomer sizes of the proteins of the small heat shock protein
family range from 12 to 43 kDa. Almost all members of this
family multimerize to form large aggregates, ranging in size
from 400 to 800 kDa with only one exception till date; sHSP
12.6 of Caenorhabditis elegans, which has the shortest N- and
C-terminal domains, is monomeric (38). The N-terminal do-
main is variable in both length and sequence in the sHSP super-
family, which might be responsible for the varying multimeric
sizes. Bova et al. (27) showed that sequential truncation from the
N terminus of aA crystallin reduces oligomeric size. In the pres-
ent study, the sequence length of the swapped N-terminal
domain between aA and aB crystallin is similar, so the varia-
tion in sequence of this domain is likely to be responsible for the
differential multimerization of the chimeric proteins.
Intrinsic and ANS Fluorescence—The emission maximum of
tryptophan is highly sensitive to solvent polarity and depends
on the accessibility of tryptophan residues to the aqueous
phase. Fig. 3 shows the intrinsic fluorescence spectra of wild-
type and chimeric proteins. The intrinsic fluorescence spectra
of the wild-type aB crystallin and aBNAC are similar. Both the
tryptophans are present in the N-terminal domain, which are
likely to be in a similar environment even after domain swap-
ping. A slight blue shift, noticeable in the red region of the
emission profile of aBNAC, compared with the wild-type aB
crystallin suggests that the tryptophans in the chimera are
marginally less solvent accessible. The intrinsic fluorescence
spectra of the lone tryptophan of wild-type aA crystallin, which
is present in the N-terminal domain, and aANBC are similar,
indicating no alteration of the tryptophan environment in the
chimeric aANBC protein with respect to the wild-type aA crys-
tallin. Fig. 4 shows the spectra of ANS in the presence of
wild-type and chimeric proteins. ANS fluorescence spectra
show marked differences in emission intensity with no appar-
ent change in emission maxima. The aANBC chimera binds the
least amount of ANS among all the proteins compared. The
aBNAC chimera, on the other hand, binds ANS several times
more when compared with wild-type aB crystallin, wild-type
aA crystallin, and aANBC chimera. This finding suggests that
there are more hydrophobic regions accessible to ANS in the
aBNAC chimera than in aANBC chimera. The molecular basis
for this finding is not yet clear. However, the gel permeation
chromatography data together with ANS fluorescence suggest
that aBNAC might be forming a large porous oligomer.
Circular Dichroism Measurements of Chimeric aANBC and
aBNAC Crystallins—Fig. 5 shows far-UV circular dichroism
spectra of wild-type and chimeric proteins. CD spectra of wild-
type aA and aB crystallins, shown in panel A, are comparable
with the CD spectra of recombinant human aA and aB crys-
FIG. 2. FPLC gel filtration profiles of wild-type aA and aB
crystallins and chimeric proteins on a Superose-6 column. A,
wild-type aA crystallin (OO) and wild-type crystallin aB (zzz). B,
aANBC chimera (OO) and aBNAC chimera (zzz). The void volume (a)
and elution positions of thyroglobulin (669 kDa) (b), ferritin (440 kDa)
(c), and catalase (232 kDa) (d) are also indicated.
FIG. 3. Intrinsic fluorescence spectra of wild-type aA crystal-
lin (E), wild-type aB crystallin ( l ), aANBC (), and aBNAC ().
Chimeric Human aA and aB Crystallins 22011
 by guest, on April 14, 2011
w
w
w
.jbc.org
D
ow
nloaded from
 
tallins reported earlier (15, 16, 26). Both the spectra show
characteristic b-sheet protein profile as expected. Chimeric
proteins also show b-sheet CD profiles. The CD spectrum of
aANBC is comparable to the spectra of wild-type aA and aB
crystallins. However, aBNAC shows increased ellipticity.
Near-UV CD spectra (Fig. 6) also show a similar trend.
Spectra of wild-type aA and aB are comparable to earlier
reported spectra for recombinant human aA and aB crystallins
(15). The CD spectrum of the chimeric aANBC is comparable to
that of aB crystallin with increased chirality for aANBC. The
CD spectrum of aBNAC on the other hand is comparable to
that of wild-type aA crystallin.
Domain swapping results in some change in secondary and
tertiary structure of aANBC with observable change only in the
secondary structure for aBNAC.
Chaperone-like Activity—Insulin B-chain aggregates in the
presence of DTT. At 37 °C a 1:1 (w/w) ratio of wild-type aA and
aB crystallin to insulin prevented this aggregation completely.
At ratios of 1:2 and 1:4, aggregation was prevented to lesser
extents, as shown in Fig. 7 (panels A and B). Interestingly, the
chimera aBNAC showed enhanced chaperone-like activity. The
initial scatter value for aBNAC chimera without insulin was
very high. The large molecular size of aBNAC could be respon-
sible for the high scatter. We had earlier observed a similar
high initial scatter value for the R116C mutant of aA crystal-
lin, which also forms a large aggregate (.2000 kDa) (16). The
data were normalized to determine the protective ability of the
aBNAC protein. At 37 °C complete protection was observed at
a 1:6 w/w ratio of aBNAC to insulin. Significant protection was
observed even at 1:8, 1:12, and 1:16 ratios of aBNAC to insulin
(Fig. 7D). The aBNAC chimera shows 3–4-fold increase in the
FIG. 4. The normalized fluorescence emission spectrum of
ANS bound to wild-type aA crystallin (E), wild-type aB crystal-
lin (l ), aANBC (), and aBNAC ().
FIG. 5. Far-UV CD spectra of wild-type aA and aB crystallins
and chimeric proteins. A, wild-type aA crystallin (zzz) and wild-type
aB crystallin (OO). B, aANBC (OO) and aBNAC (zzz). The samples
were prepared in 50 mM Tris-HCl buffer, pH 7.4, containing 100 mM
NaCl and 1 mM EDTA.
FIG. 6. Near-UV CD spectra of wild-type aA and aB crystallins
and chimeric proteins. A, wild-type aA crystallin (zzz) and wild-type
aB crystallin (OO). B, aANBC (OO) and aBNAC (zzz). The samples
were prepared in 50 mM Tris-HCl buffer, pH 7.4, containing 100 mM
NaCl and 1 mM EDTA.
FIG. 7. Chaperone-like activity of wild-type aA and aB crystal-
lins and chimeric proteins. A, effect of wild-type aA crystallin.
DTT-induced aggregation of 0.2 mg/ml insulin alone (Ins) and in the
presence of 1:1, 1:2, and 1:4 w/w wild-type aA crystallin:insulin, respec-
tively. B, effect of wild-type aB crystallin. Panel shows aggregation of
0.2 mg/ml insulin alone (Ins) and in the presence of 1:1, 1:2, and 1:4 w/w
wild-type aB crystallin:insulin, respectively. C, effect of aANBC chi-
mera. Panel shows aggregation of 0.2 mg/ml insulin alone (Ins) and in
the presence of 1:2 and 1:1 w/w aANBC:insulin, respectively. D, effect of
aBNAC chimera. Panel shows aggregation of 0.2 mg/ml insulin alone
(Ins) and in the presence of 1:6 1:8, 1:12, and 1:16 w/w aBNAC:insulin,
respectively.
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chaperone-like activity compared with the wild-type proteins.
aANBC, in contrast, shows complete loss of chaperone-like
activity. A 1:2 (w/w) ratio of aANBC to insulin does not show
any protective ability toward DTT-induced aggregation of in-
sulin. Increasing the aANBC ratios to 1:1 and 2:1 w/w with
respect to insulin does not show any increase in protection (Fig.
7C). In fact, aANBC promotes the aggregation process as ob-
served by increased light scattering.
The swapped N-terminal domain (exon 1 encoded) is compa-
rable in length between human aA and aB crystallins. There
are some differences in the sequences in this region. One of the
prominent differences is the increase in the number of proline
residues. The N-terminal domain of aA crystallin contains 5
proline residues, whereas the same region for aB crystallin has
9 proline residues (two prolines in tandem). The swapping
alters the number of proline residues in the chimeric proteins.
aBNAC contains 9 prolines in its N-terminal domain, a gain of
4 prolines in comparison to the same region of wild-type aA
crystallin. Far-UV CD spectrum shows some enhancement in
the secondary structure. Whether the local secondary struc-
tural changes can alter the subunit topology and consequently
intersubunit interactions remains to be investigated. Although
we point out differences in the number of proline residues,
there are other sequence variations, and marginal changes in
predicted pI and the total length of the chimeric proteins.
Clearly discernible changes are oligomeric status, accessible
hydrophobic surfaces, and chaperone-like activity.
It is interesting to note that, despite being similar to wild-
type aB crystallin in the aggregate molecular mass and circular
dichroism spectra, the chimeric aANBC possesses no chaper-
one-like activity. The most important difference between the
two chimeric proteins is the accessible hydrophobicity. ANS, a
hydrophobicity probe, very clearly distinguishes the two chi-
meric proteins. We believe that the lack of accessible surface
hydrophobicity, probably due to altered subunit packing in
aANBC chimera, results in its loss of chaperone-like activity.
The enhanced chaperone-like activity of aBNAC chimera
could be because of the exposure and availability of more hy-
drophobic surfaces when compared with the wild-type proteins.
Increased ANS binding of the aBNAC chimera supports this
possibility. We observed an increase in oligomeric size and
chaperone-like activity in the case of the aBNAC chimera.
However, the increase in size and enhancement of chaperone-
like activity may not be necessarily correlated. The point mu-
tation R116C in aA crystallin leads to increased oligomer size
but results in significant loss of chaperone-like activity. Swap-
ping the N-terminal domain between human aA and aB crys-
tallins makes a more effective chaperone in the case of aBNAC
chimera, whereas aANBC chimera loses its protective abilities
completely. To the best of our knowledge, this is the first report
where a 3–4-fold increase in chaperone-like activity is ob-
served. This phenomenon may have a therapeutic significance
in diseases occurring due to protein misfolding.
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